Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

The Long and Complicated Relationship between Epstein-Barr Virus and Epithelial Cells.

Hutt-Fletcher LM.

J Virol. 2016 Dec 16;91(1). pii: e01677-16. doi: 10.1128/JVI.01677-16. Print 2017 Jan 1. Review.

2.

Braving the New World.

Hutt-Fletcher LM.

PLoS Pathog. 2016 Apr 28;12(4):e1005417. doi: 10.1371/journal.ppat.1005417. eCollection 2016 Apr. No abstract available.

3.

The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells.

Gram AM, Oosenbrug T, Lindenbergh MF, Büll C, Comvalius A, Dickson KJ, Wiegant J, Vrolijk H, Lebbink RJ, Wolterbeek R, Adema GJ, Griffioen M, Heemskerk MH, Tscharke DC, Hutt-Fletcher LM, Wiertz EJ, Hoeben RC, Ressing ME.

PLoS Pathog. 2016 Apr 14;12(4):e1005550. doi: 10.1371/journal.ppat.1005550. eCollection 2016 Apr.

4.
5.

EBV glycoproteins: where are we now?

Hutt-Fletcher LM.

Future Virol. 2015;10(10):1155-1162.

6.

Epstein-Barr virus glycoprotein gM can interact with the cellular protein p32 and knockdown of p32 impairs virus.

Changotra H, Turk SM, Artigues A, Thakur N, Gore M, Muggeridge MI, Hutt-Fletcher LM.

Virology. 2016 Feb;489:223-32. doi: 10.1016/j.virol.2015.12.019. Epub 2016 Jan 13.

7.

Alcelaphine herpesvirus 1 glycoprotein B: recombinant expression and antibody recognition.

Dry I, Todd H, Deane D, Percival A, Mclean K, Inglis NF, Manson ED, Haig DM, Nayuni S, Hutt-Fletcher LM, Grant DM, Bartley K, Stewart JP, Russell GC.

Arch Virol. 2016 Mar;161(3):613-9. doi: 10.1007/s00705-015-2701-y. Epub 2015 Dec 9.

8.

Viral Entry.

Chesnokova LS, Jiang R, Hutt-Fletcher LM.

Curr Top Microbiol Immunol. 2015;391:221-35. doi: 10.1007/978-3-319-22834-1_7. Review.

PMID:
26428376
9.

Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells.

Xiong D, Du Y, Wang HB, Zhao B, Zhang H, Li Y, Hu LJ, Cao JY, Zhong Q, Liu WL, Li MZ, Zhu XF, Tsao SW, Hutt-Fletcher LM, Song E, Zeng YX, Kieff E, Zeng MS.

Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):11036-41. doi: 10.1073/pnas.1513359112. Epub 2015 Aug 19.

10.

Epstein-Barr virus replicating in epithelial cells.

Hutt-Fletcher LM.

Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16242-3. doi: 10.1073/pnas.1418974111. Epub 2014 Nov 10. No abstract available.

11.

Epstein-Barr virus infection mechanisms.

Chesnokova LS, Hutt-Fletcher LM.

Chin J Cancer. 2014 Nov;33(11):545-8. doi: 10.5732/cjc.014.10168. Epub 2014 Oct 17. Review.

12.

Epstein-Barr virus glycoprotein gB and gHgL can mediate fusion and entry in trans, and heat can act as a partial surrogate for gHgL and trigger a conformational change in gB.

Chesnokova LS, Ahuja MK, Hutt-Fletcher LM.

J Virol. 2014 Nov;88(21):12193-201. doi: 10.1128/JVI.01597-14. Epub 2014 Aug 20.

13.

Association between human papilloma virus/Epstein-Barr virus coinfection and oral carcinogenesis.

Jiang R, Ekshyyan O, Moore-Medlin T, Rong X, Nathan S, Gu X, Abreo F, Rosenthal EL, Shi M, Guidry JT, Scott RS, Hutt-Fletcher LM, Nathan CA.

J Oral Pathol Med. 2015 Jan;44(1):28-36. doi: 10.1111/jop.12221. Epub 2014 Jul 18.

14.

αvβ6- and αvβ8-integrins serve as interchangeable receptors for HSV gH/gL to promote endocytosis and activation of membrane fusion.

Gianni T, Salvioli S, Chesnokova LS, Hutt-Fletcher LM, Campadelli-Fiume G.

PLoS Pathog. 2013;9(12):e1003806. doi: 10.1371/journal.ppat.1003806. Epub 2013 Dec 19.

15.

αvβ3-integrin is a major sensor and activator of innate immunity to herpes simplex virus-1.

Gianni T, Leoni V, Chesnokova LS, Hutt-Fletcher LM, Campadelli-Fiume G.

Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19792-7. doi: 10.1073/pnas.1212597109. Epub 2012 Nov 12.

16.

Oral dysplasia and squamous cell carcinoma: correlation between increased expression of CD21, Epstein-Barr virus and CK19.

Jiang R, Gu X, Moore-Medlin TN, Nathan CA, Hutt-Fletcher LM.

Oral Oncol. 2012 Sep;48(9):836-41. doi: 10.1016/j.oraloncology.2012.03.017. Epub 2012 Apr 16.

17.

Important but differential roles for actin in trafficking of Epstein-Barr virus in B cells and epithelial cells.

Valencia SM, Hutt-Fletcher LM.

J Virol. 2012 Jan;86(1):2-10. doi: 10.1128/JVI.05883-11. Epub 2011 Oct 26.

18.
19.

Laser capture microdissection for analysis of gene expression in formalin-fixed paraffin-embedded tissue.

Jiang R, Scott RS, Hutt-Fletcher LM.

Methods Mol Biol. 2011;755:77-84. doi: 10.1007/978-1-61779-163-5_6.

PMID:
21761295
20.

Integrins as triggers of Epstein-Barr virus fusion and epithelial cell infection.

Hutt-Fletcher LM, Chesnokova LS.

Virulence. 2010 Sep-Oct;1(5):395-8. doi: 10.4161/viru.1.5.12546. Review.

21.

Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8.

Chesnokova LS, Nishimura SL, Hutt-Fletcher LM.

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20464-9. doi: 10.1073/pnas.0907508106. Epub 2009 Nov 17. Erratum in: Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3275.

22.

The BDLF2 protein of Epstein-Barr virus is a type II glycosylated envelope protein whose processing is dependent on coexpression with the BMRF2 protein.

Gore M, Hutt-Fletcher LM.

Virology. 2009 Jan 5;383(1):162-7. doi: 10.1016/j.virol.2008.10.010. Epub 2008 Nov 7.

23.

Epstein-Barr virus LF2: an antagonist to type I interferon.

Wu L, Fossum E, Joo CH, Inn KS, Shin YC, Johannsen E, Hutt-Fletcher LM, Hass J, Jung JU.

J Virol. 2009 Jan;83(2):1140-6. doi: 10.1128/JVI.00602-08. Epub 2008 Nov 5.

24.
25.

Epstein-Barr virus entry.

Hutt-Fletcher LM.

J Virol. 2007 Aug;81(15):7825-32. Epub 2007 Apr 25. Review. No abstract available.

26.

Point mutations in EBV gH that abrogate or differentially affect B cell and epithelial cell fusion.

Wu L, Hutt-Fletcher LM.

Virology. 2007 Jun 20;363(1):148-55. Epub 2007 Feb 20.

27.

Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells.

Turk SM, Jiang R, Chesnokova LS, Hutt-Fletcher LM.

J Virol. 2006 Oct;80(19):9628-33.

28.

Epstein-Barr virus shed in saliva is high in B-cell-tropic glycoprotein gp42.

Jiang R, Scott RS, Hutt-Fletcher LM.

J Virol. 2006 Jul;80(14):7281-3.

29.
30.

Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion.

Ressing ME, van Leeuwen D, Verreck FA, Keating S, Gomez R, Franken KL, Ottenhoff TH, Spriggs M, Schumacher TN, Hutt-Fletcher LM, Rowe M, Wiertz EJ.

J Virol. 2005 Jan;79(2):841-52.

31.

Use of gHgL for attachment of Epstein-Barr virus to epithelial cells compromises infection.

Borza CM, Morgan AJ, Turk SM, Hutt-Fletcher LM.

J Virol. 2004 May;78(10):5007-14.

32.
33.

Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition.

Ressing ME, van Leeuwen D, Verreck FA, Gomez R, Heemskerk B, Toebes M, Mullen MM, Jardetzky TS, Longnecker R, Schilham MW, Ottenhoff TH, Neefjes J, Schumacher TN, Hutt-Fletcher LM, Wiertz EJ.

Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11583-8. Epub 2003 Sep 22.

34.
35.

Two Epstein-Barr virus glycoprotein complexes.

Hutt-Fletcher LM, Lake CM.

Curr Top Microbiol Immunol. 2001;258:51-64. Review. No abstract available.

PMID:
11443867
36.

EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma.

Ruf IK, Rhyne PW, Yang H, Borza CM, Hutt-Fletcher LM, Cleveland JL, Sample JT.

Curr Top Microbiol Immunol. 2001;258:153-60. Review. No abstract available.

PMID:
11443860
37.

Biosynthetic radiolabeling of virus glycoproteins for immunoprecipitation and electrophoretic analysis.

Hutt-Fletcher LM, Turk SM.

Methods Mol Biol. 2001;174:243-6. No abstract available.

PMID:
11357651
38.

Virus isolation.

Hutt-Fletcher LM, Turk SM.

Methods Mol Biol. 2001;174:119-23. No abstract available.

PMID:
11357633
39.
40.

Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells.

Molesworth SJ, Lake CM, Borza CM, Turk SM, Hutt-Fletcher LM.

J Virol. 2000 Jul;74(14):6324-32.

41.

Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma.

Ruf IK, Rhyne PW, Yang H, Borza CM, Hutt-Fletcher LM, Cleveland JL, Sample JT.

Mol Cell Biol. 1999 Mar;19(3):1651-60.

44.

Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells.

Wang X, Kenyon WJ, Li Q, Müllberg J, Hutt-Fletcher LM.

J Virol. 1998 Jul;72(7):5552-8.

45.
46.

Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes.

Li Q, Spriggs MK, Kovats S, Turk SM, Comeau MR, Nepom B, Hutt-Fletcher LM.

J Virol. 1997 Jun;71(6):4657-62.

47.

Chaperone functions common to nonhomologous Epstein-Barr virus gL and Varicella-Zoster virus gL proteins.

Li Q, Buranathai C, Grose C, Hutt-Fletcher LM.

J Virol. 1997 Feb;71(2):1667-70.

49.

A novel Epstein-Barr virus glycoprotein gp150 expressed from the BDLF3 open reading frame.

Kurilla MG, Heineman T, Davenport LC, Kieff E, Hutt-Fletcher LM.

Virology. 1995 May 10;209(1):108-21.

50.

Supplemental Content

Loading ...
Support Center